2.0
8 May 2023
Anonymous employee
Former employee, more than 3 years
Recommend
CEO approval
Business outlook
Pros
Overwhelming commitment to the mission. Most everyone sincerely cared about serving vulnerable transplant patients through noninvasive rejection testing.
Cons
Perhaps it was doomed from the start? Launching a test for immunocompromised patients right before the COVID-19 pandemic started was horrible luck. It took a lot longer to gain traction in the marketplace, which made it difficult to ever hit the aggressive growth forecast Eurofins had for TGI. The death knell came with the Medicare reimbursement changes in April 2023 which cut the company revenue by more than half, leading to a massive layoff.